The Manila Times12h
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
"We are excited to initiate the Phase 3 study and we believe that Piclidenoson's oral dosage and excellent safety record, ...
The best early deals of Amazon’s Big Spring Sale
Spring is here, and Amazon is dropping deals on everything from water bottles and dresses to self-care items and outdoor ...
Le Lézard13h
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, ...
Can-Fite BioPharma Ltd.: Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) ...
Rolling Out13h
The battle between butter and plant oils in everyday diets
Uncover how butter and plant oils affect your health and why small dietary changes may have a lasting impact on well-being.
Dermatology Advisor11h
Risankizumab May Be Superior to Other Biologic Therapies in Plaque Psoriasis
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Frontiers17h
New Insights into Inflammation Driven Autoimmune Skin Disorders: Trends and Challenges
In the realm of dermatology, inflammatory skin disorders encompass a wide array of skin related serious conditions such as systemic lupus erythematosus, ...